CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 30,415 enrolled
Drug / intervention
mRNA-1273 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04470427
NCT04470427Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older

ModernaTX, Inc.·interventional·Posted Jul 14, 2020·Updated Mar 21, 2024

In Brief

A Phase 3 clinical trial evaluating mRNA-1273 and Placebo for SARS-CoV-2. Completed, enrolled 30,415 participants across 100 sites.

Detailed Summary

The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
CollaboratorsBiomedical Advanced Research and Development Authority, National Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJul 14, 2020
Enrollment StartJul 27, 2020
Primary CompletionDec 29, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.0 years ago

Interventions

mRNA-1273biological

Sterile liquid for injection

Placebobiological

0.9% sodium chloride (normal saline) injection